Search

The Czech medicines regulator SÚKL has granted consent to begin phase II B clinical evaluation of DUOFAG®. This follows completed phase I, which confirmed the product’s safety, and ongoing phase II A examining efficacy in patients with comp

An ANSM letter dated May 28, 2026 authorized HCL to manufacture production intermediates and purified therapeutic phage pharmaceutical raw materials under GMP standards. Its PHAGEinLYON programme began in 2017. Hospices Civils de Lyon — exa

Ottignies-Louvain-La-Neuve, Belgium As a Chief Medical Officer, you will be accountable for Inteliphage’s medical strategy and for the clinical development of its Phage Therapy Medicinal Product (PTMP) portfolio. You will convert an advanc